OPKO Health, Inc.
OPK.TA
Tel Aviv Stock Exchange458.50
ILA
-3.30
- -
OPKO Health, Inc.
OPK.TA
(Tel Aviv Stock Exchange)
Recent
price
458.50
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- OPKO Health, Inc. (Nasdaq: OPK; TASE: OPK) is a multinational biopharmaceutical and diagnostics company that discovers, develops, manufactures, and commercializes proprietary pharmaceuticals, diagnostic tests, and laboratory services for serious diseases including chronic kidney disease, growth hormone deficiency, prostate cancer, oncology, and infectious diseases; core products and services include the Rayaldee extended-release calcifediol capsule for secondary hyperparathyroidism; the 4Kscore Test for assessing aggressive prostate cancer risk; VARUBI oral suspension for chemotherapy-induced nausea and vomiting; the BioReference Laboratories network offering clinical reference testing in genetics, oncology, women's health, and urology across the United States with core operations in New York and New Jersey; point-of-care tests, molecular diagnostics, and advanced imaging technologies; biologic therapies such as monoclonal antibodies; and multispecific antibody programs targeting cancers, immunology, metabolic diseases, influenza, and COVID-19 through subsidiaries and partnerships. Founded in 1991 and headquartered in Miami, Florida, the company operates globally with established markets in North America, Europe, and beyond, serving physicians, patients, hospitals, and pharmaceutical partners through its diversified segments of pharmaceuticals and diagnostics. Recent developments include the March 2025 agreement and September 2025 completion of Labcorp's acquisition of select BioReference Health oncology and clinical testing assets for up to $225 million to streamline operations and focus on core testing and the 4Kscore franchise; a July 2024-initiated and April 2025-expanded $200 million common stock repurchase program with $41 million repurchased by April; $51 million in additional BARDA funding awarded in early 2025 for ModeX Therapeutics' COVID-19 multispecific antibodies and influenza programs, bringing total awards to $110 million; enrollment in the MDX2001 Phase 1 trial for tetraspecific antibodies in solid tumor cancers; and a November 2025 collaboration with Regeneron involving a $7 million upfront payment, over $200 million per-molecule milestones, low double-digit royalties, and potential value exceeding $1 billion for multispecific therapeutics in immunology, oncology, and metabolic diseases.